Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial

ANNÉE

2022

AUTEURS

Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P, Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group

CONGRÈS/REVUE

JAMA Oncol

LIEN PUBLICATIONS ASSOCIÉES